EUVIMEDEUVIMED entdecken
Crossref

Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma

Stefano Francesco Crinò, Bertrand Napoleon, Antonio Facciorusso, Sundeep Lakhtakia, Ivan Borbath, Fabrice Caillol, Khanh Do-Cong Pham, Gianenrico Rizzatti, Edoardo Forti, Laurent Palazzo, Arthur Belle, Peter Vilmann und 16 weitere

Clinical Gastroenterology and Hepatology · 2023-10 · 21 (11) · 2834-2843.e2

DOI: 10.1016/j.cgh.2023.02.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-10. Verfasst von Stefano Francesco Crinò und 27 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Endoscopy Unit, The Pancreas Institute, University Hospital of Verona, Verona, Italy. Electronic address: stefanofrancesco.crino@aovr.venet…. Hauptthemen laut MEDLINE: Insulinoma, Pancreatic Neoplasms, Radiofrequency Ablation, Catheter Ablation. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is emerging as a safe and effective treatment for pancreatic neuroendocrine tumors. We aimed to compare EUS-RFA and surgical resection for the treatment of pancreatic insulinoma (PI). METHODS: Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis. Primary outcome was safety. Secondary outcomes were clinical efficacy, hospital stay, and recurrence rate after EUS-RFA. RESULTS: Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160). However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients). CONCLUSION: EUS-RFA is safer than surgery and highly effective for the treatment of PI. If confirmed in a randomized study, EUS-RFA treatment can become first-line therapy for sporadic PI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaPancreatic NeoplasmsRadiofrequency AblationCatheter AblationHumansRetrospective StudiesTreatment OutcomeUltrasonography, Interventional

Stichwörter der Autor:innen

Acute pancreatitisHypoglycemiaInsulinNeuroendocrine TumorPancreatic Fistula

Autor:innen und Institutionen

  • Digestive Endoscopy Unit, The Pancreas Institute, University Hospital of Verona, Verona, Italy. Electronic address: stefanofrancesco.crino@aovr.veneto.it.
  • Service de Gastroentérologie, Hôpital Privé Jean Mermoz, Ramsay Générale de Santé, Lyon, France.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Asian Institute of Gastroenterology, Hyderabad, India.
  • Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium.
  • Endoscopy Unit, Paoli Calmettes Institute, Marseille, France.

Zitieren

APA

Crinò, S. F., Napoleon, B., Facciorusso, A., Lakhtakia, S., Borbath, I., Caillol, F., Do-Cong Pham, K., Rizzatti, G., Forti, E., Palazzo, L., Belle, A., Vilmann, P., van Laethem, J. L., Mohamadnejad, M., Godat, S., Hindryckx, P., Benson, A., Tacelli, M., De Nucci, G., …, & Larghi, A. (2023). Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clinical Gastroenterology and Hepatology, 21(11), 2834-2843.e2. https://doi.org/10.1016/j.cgh.2023.02.022

Vancouver

Crinò SF, Napoleon B, Facciorusso A, Lakhtakia S, Borbath I, Caillol F, et al. Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clinical Gastroenterology and Hepatology. 2023;21(11):2834-2843.e2. doi:10.1016/j.cgh.2023.02.022

BibTeX
@article{Crin2023,
  author = {Crinò, Stefano Francesco and Napoleon, Bertrand and Facciorusso, Antonio and Lakhtakia, Sundeep and Borbath, Ivan and Caillol, Fabrice and Do-Cong Pham, Khanh and Rizzatti, Gianenrico and Forti, Edoardo and Palazzo, Laurent and Belle, Arthur and Vilmann, Peter and van Laethem, Jean-Luc and Mohamadnejad, Mehdi and Godat, Sebastien and Hindryckx, Pieter and Benson, Ariel and Tacelli, Matteo and De Nucci, Germana and Binda, Cecilia and Kovacevic, Bojan and Jacob, Harold and Partelli, Stefano and Falconi, Massimo and Salvia, Roberto and Landoni, Luca and ERASING study collaborators, ERASING study collaborators and Larghi, Alberto},
  title = {Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {11},
  pages = {2834--2843.e2},
  doi = {10.1016/j.cgh.2023.02.022}
}
Kostenlos starten →